Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00380653 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes
A Phase 1 study, sponsored by Cyclacel Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT00380653 is a Phase 1 study that has completed, run by Cyclacel Pharmaceuticals. The registered enrollment target is 47 participants.
The verdict
NCT00380653, a Phase 1 study, has completed, sponsored by Cyclacel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The goal of this safety/pharmacology study is to determine MTD of sapacitabine when administered in patients with advanced leukemias or myelodysplastic syndromes.
Interventions
- DRUG sapacitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2006-01 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00380653
The ClinicalTrials.gov registry entry for NCT00380653 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cyclacel Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sapacitabine is the first listed.
NCT00380653 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00380653 about?
NCT00380653 is a clinical study titled "Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes". The goal of this safety/pharmacology study is to determine MTD of sapacitabine when administered in patients with advanced leukemias or myelodysplastic syndromes.
What is the current status of trial NCT00380653?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2006-01. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00380653?
The interventions under investigation include: sapacitabine (DRUG).
Who is sponsoring clinical trial NCT00380653?
This trial is sponsored by Cyclacel Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.